Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated enterovirus 71 vaccine + measles attenuated live vaccine
- Development stage
- Unknown
- Lead developer
- Chinese Academy of Medical Sciences
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The **inactivated enterovirus 71 vaccine + measles attenuated live vaccine** refers to a combination immunization regimen or potential combination vaccine product consisting of an inactivated Enterovirus 71 (EV71) vaccine and a live attenuated measles vaccine. The EV71 component, specifically the inactivated vaccine developed by the Institute of Medical Biology at the Chinese Academy of Medical Sciences (IMBCAMS) using human diploid cells (KMB-17), is designed to prevent hand, foot, and mouth disease (HFMD) and its associated neurological complications. The measles component is a live attenuated virus vaccine intended to provide immunity against measles. Clinical studies, including Phase 4 trials, have evaluated the safety and immunogenicity of co-administering these vaccines at the same time point in infants (typically 8 months of age) to simplify the pediatric immunization schedule without compromising the protective efficacy of either component.
- Brand names
- Inlive
- Other names
- EV71 + measles attenuated live vaccineinactivated Enterovirus 71 vaccine and measles attenuated live vaccine co-administrationEV71 vaccine + measles vaccine
02
Targets
Enterovirus A71 capsid proteinMV (Measles virus)
Beyond the preview
Go deeper on inactivated enterovirus 71 vaccine + measles attenuated live vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated enterovirus 71 vaccine + measles attenuated live vaccine.